Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability

• Published in: International journal of molecular sciences Vol. 23; no. 16; p. 9371
• Main Authors: Baldasici, Oana, Pileczki, Valentina, Cruceriu, Daniel, Gavrilas, Laura Ioana, Tudoran, Oana, Balacescu, Loredana, Vlase, Laurian, Balacescu, Ovidiu
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19.08.2022; MDPI
• Subjects: biomarker; Biomarkers; Biopsy; Breast cancer; Evolution; Exosomes; extracellular vesicles; Gene expression; Genotype & phenotype; Lymphatic system; Medical prognosis; Metastases; Metastasis; Microenvironments; MicroRNAs; miRNA; Patients; Protein transport; Review; Tumors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23169371

Metastasis represents the most important cause of breast cancer-associated mortality. Even for early diagnosed stages, the risk of metastasis is significantly high and predicts a grim outcome for the patient. Nowadays, efforts are made for identifying blood-based biomarkers that could reliably distinguish patients with highly metastatic cancers in order to ensure a closer follow-up and a more personalized therapeutic method. Exosomes are nano vesicles secreted by cancer cells that can transport miRNAs, proteins, and other molecules and deliver them to recipient cells all over the body. Through this transfer, cancer cells modulate their microenvironment and facilitate the formation of the pre-metastatic niche, leading to sustained progression. Exosomal miRNAs have been extensively studied due to their promising potential as prognosis biomarkers for metastatic breast cancer. In this review, we tried to depict an overview of the existing literature regarding exosomal miRNAs that are already validated as potential biomarkers, and which could be immediately available for the clinic. Moreover, in the last section, we highlighted several miRNAs that have proven their function in preclinical studies and could be considered for clinical validation. Considering the lack of standard methods for evaluating exosomal miRNA, we also discussed the challenges and the technical aspects underlying this issue.